These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11195041)

  • 1. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression.
    Benigni A; Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):1-6. PubMed ID: 11195041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endothelin system and endothelin receptor antagonists.
    Jandeleit-Dahm KA; Watson AM
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies.
    Ruggenenti P
    Semin Nephrol; 2004 Mar; 24(2):158-67. PubMed ID: 15017528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How renal cytokines and growth factors contribute to renal disease progression.
    Benigni A; Remuzzi G
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S21-4. PubMed ID: 11158856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic measures in proteinuric nephropathy.
    Praga M
    Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
    Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
    Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
    Tylicki L; Lizakowski S; Rutkowski B
    J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective therapy in patients with nondiabetic nephropathies.
    Pisoni R; Ruggenenti P; Remuzzi G
    Drugs; 2001; 61(6):733-45. PubMed ID: 11398906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin antagonists and renal protection.
    Benigni A; Perico N; Remuzzi G
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S75-78. PubMed ID: 10976787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists and treatment of hypertension and renal disease.
    Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):571-8. PubMed ID: 9818206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases.
    Luft FC
    Curr Opin Nephrol Hypertens; 2002 Jan; 11(1):59-66. PubMed ID: 11753088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
    Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
    Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
    Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin antagonism and reversal of proteinuric renal disease in humans.
    Barton M
    Contrib Nephrol; 2011; 172():210-222. PubMed ID: 21894001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.
    Dhaun N; Macintyre IM; Melville V; Lilitkarntakul P; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2009 Sep; 54(3):e19-20. PubMed ID: 19652085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.